Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.580
-0.040 (-0.87%)
At close: Apr 28, 2026, 4:00 PM EDT
4.770
+0.190 (4.15%)
After-hours: Apr 28, 2026, 7:03 PM EDT
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 2.80M AUD in the half year ending December 31, 2025, with 47.49% growth. This brings the company's revenue in the last twelve months to 6.64M, up 78.18% year-over-year. In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M with 35.32% growth.
Revenue (ttm)
6.64M AUD
Revenue Growth
+78.18%
P/S Ratio
17.62
Revenue / Employee
737,380 AUD
Employees
9
Market Cap
78.00M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
| Jun 30, 2021 | 4.34M | - | - |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 57.95M |
| Q32 Bio | 53.74M |
| Gossamer Bio | 48.47M |
| Sangamo Therapeutics | 39.55M |
| NeurAxis | 3.57M |
| eXoZymes | -700.00 |
ATHE News
- 1 day ago - Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development - GuruFocus
- 1 day ago - Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study - Nasdaq
- 1 day ago - Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy - GlobeNewsWire
- 6 days ago - Alterity Therapeutics (ATHE) Shows Promising Results in Phase 2 Trial for MSA - GuruFocus
- 6 days ago - Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology - GlobeNewsWire
- 11 days ago - Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics (ATHE) Prepares for Phase 3 Trial After FDA Feedback - GuruFocus
- 4 weeks ago - Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program - GlobeNewsWire